ReviewDose issues in antiepileptic therapy
Introduction
The positive pharmacological effects of drugs, as well as their adverse effects, are related to their dose, which has been known since Paracelsus (1493–1541), a Swiss physician born Theophrastus Phillipus Aureolus Bombastus von Hohenheim, developed a new approach to medicine and philosophy based on observation and experience.
Kim Meador, a leader in the field of research on cognition in epilepsy, has acknowledged the question of dose-related drug effects and referred to Paracelsus in characterising adverse cognitive outcomes related to dosing.1 Recent publications from the international Pregnancy Register EURAP,2 and by Jentink et al.3 on teratogenicity, recognise the validity of a dose-related approach to AED toxicity.
Clinicians have overlooked this issue for decades, ignored dose-related problems and used AED with less than ideal caution. AED have a low therapeutic index, which means that a dose producing benefits may not be much less than a dose producing harm. Stability of doses and of plasma levels is important, and switching medications from generic to designer drugs and vice versa is not recommended by the American Academy of Neurology nor the Epilepsy Society of Australia.
The individual AED illustrate these problems.
Section snippets
Phenobarbitone
This group of drugs is fortunately no longer used as first line. Phenobarbitone and its congeners, methyphenobarbitone and mysoline, are highly effective, but difficult to withdraw. They cause somnolence, habituation, as well as narcosis, in high dose. They are enzyme inducers. The resultant effect on other drugs may be to lower their effectiveness; barbiturates have been repeatedly shown to be teratogenic in a dose-related manner.2, 4
Phenytoin
Phenytoin presents many dose-related problems, especially
Antiepileptic drugs and foetal malformations
Extensive early uncontrolled data, mostly from retrospective studies, suggested for almost three decades that it is not the epilepsy but the use of AED that is predominantly responsible for foetal malformations (FM) in pregnant women with epilepsy. Since the early 2000s, this observation has been complicated by the recognition of cognitive adverse effects on the foetus by the AED.
Initially, a lack of uniformity in data collection hindered a clear-cut definition of the problem of teratogenicity.
Summary
Antiepileptic drug therapy has been highlighted to focus on the profound potential adverse effects due to AED, of which teratogenicity appears the most serious and devastating. These drugs are capable of causing physical malformations, such as neural tube defect, but also possibly cause impaired cognitive development of the foetus. The latter may involve a lower intelligence quotient, language problems, lowered executive skills and autism. It appears that AED doses have a major bearing on these
Conflicts of interest/Disclosures
The Australian Pregnancy Register is indebted for support from the Epilepsy Society of Australia and the Royal Melbourne Hospital Neuroscience Foundation, and financial support from the pharmaceutical industry: Sanofi-Synthelabo, UCB Pharma, Janssen Cilag, Novartis and Sci Gen. The authors declare that they have no further disclosures or conflicts of interest in relation to this research and its publication.
Acknowledgment
I wish to acknowledge the support of MJ Eadie, TJ O’Brien, CM Lander and J Graham.
References (19)
- et al.
Dose-dependent risk of malformations with antiepileptic drugs: an analysis of data from the EURAP epilepsy and pregnancy registry
Lancet Neurol
(2011) - et al.
Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 study group
Epilepsy Res
(1997) - et al.
Teratogenicity of the newer antiepileptic drugs – the Australian experience
J Clin Neurosci
(2012) - et al.
Cognitive function at 3 years of age after fetal exposure to antiepileptic drugs
N Engl J Med
(2009) - et al.
For the EUROCAT antiepileptic study working group. Maternal use of antiepileptic drugs and the risk of major congenital malformations
JAMA
(2011) - et al.
The teratogenicity of anticonvulsant drugs
N Engl J Med
(2001) - et al.
Management of epilepsy with diphenylhydantoin sodium dosage regulation for problem patients
JAMA
(1968) Monitoring antiepileptic drug therapy with serum level measurements
Med J Aust
(2007)- et al.
Association between HLA-B∗ 1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese
Epilepsia
(2007)
Cited by (13)
A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid
2023, Saudi Pharmaceutical JournalCitation Excerpt :HDAC suppression and the formation of ROS (reactive oxygen species) are particularly important during the first three months of pregnancy when DNA dysregulation has the greatest impact on fetal organogenesis (Lloyd, 2013). VPA deposits in the embryo's circulation in the majority of the cases, reaching higher concentrations than those present in the blood of the mother; which may be accountable for the toxic effects and a higher threat (about threefold) of teratogenicity (Vajda, 2012). On the other hand, because the fetus' defense system is immature in the first three months of pregnancy, ROS produced by bioactivation of VPA impede ETC (electron transport chain) for energy creation, limiting the detoxification process and boosting interactions of ROS with biomolecules such as DNA (Lloyd, 2013).
The Australian Register of Antiepileptic Drugs in Pregnancy: Changes over time in the epileptic population
2014, Journal of Clinical NeuroscienceCitation Excerpt :The altered patterns of AED prescribing probably reflect increased professional acceptance of the potential advantages of using a single AED where possible, and the increasing use of newer AED with overall more desirable pharmacokinetic and adverse effect profiles, albeit with less available information about their human teratogenic potential. The decreased use of valproate, and its use in lower dosages, almost certainly a consequence of information, some of it derived from the Register itself [6–8], becoming more widely available that indicates that the drug is a dose-related teratogen. Although overall foetal malformation rates did not differ between the two cohorts, a separate analysis has shown that spina bifida rates have fallen.
Exploring phytotherapeutic approach in the management of valproic acid-induced toxicity
2023, Advances in Traditional MedicineCanagliflozin alleviates valproic acid-induced autism in rat pups: Role of PTEN/PDK/PPAR-γ signaling pathways
2023, Frontiers in PharmacologyThe teratogenic effect of pregabalin on heart, liver and kidney in rats: a light microscopic, electron microscopic and immunohistochemical study
2022, BMC Pharmacology and ToxicologyEmbryonic Hypotaurine Levels Contribute to Strain-Dependent Susceptibility in Mouse Models of Valproate-Induced Neural Tube Defects
2022, Frontiers in Cell and Developmental Biology